Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifibrinolytics for heavy menstrual bleeding.

A Lethaby1, C Farquhar, I Cooke

  • 1Department of Obstetrics and Gynaecology, University of Auckland, 2nd Floor, National Women's Hospital, Claude Road, Epsom, Auckland, New Zealand. a.lethaby@auckland.ac.nz

The Cochrane Database of Systematic Reviews
|October 18, 2000
PubMed
Summary

Antifibrinolytic agents significantly reduce heavy menstrual bleeding (HMB) compared to placebo and other medical treatments. Tranexamic acid improves quality of life without increasing side effects, though patient perception and thromboembolic event data require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV and diabetes impair <i>M. tuberculosis</i>-specific interferon-gamma responses on QuantiFERON-TB Gold Plus testing.

IJTLD open·2024
Same author

Alcohol use among people who inject drugs living with HIV in Kenya is associated with needle sharing, more new sex partners, and lower engagement in HIV care.

AIDS and behavior·2023
Same author

Access to Workplace Supports is Positively Associated with Exclusive Breastfeeding among Formally Employed Mothers in Kenya.

The Journal of nutrition·2022
Same author

Formal maternal employment is associated with lower odds of exclusive breastfeeding by 14 weeks postpartum: a cross-sectional survey in Naivasha, Kenya.

The American journal of clinical nutrition·2021
Same author

Re: The effect of new cross linked hyaluronan gel on quality of life of patients after deep infiltrating endometriosis surgery: a randomised controlled pilot study.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2021
Same author

AmAMP1 from Acropora millepora and damicornin define a family of coral-specific antimicrobial peptides related to the Shk toxins of sea anemones.

Developmental and comparative immunology·2020

Area of Science:

  • Gynecology
  • Pharmacology
  • Clinical Trials

Background:

  • Heavy menstrual bleeding (HMB) affects many women, with medical therapies offering an alternative to surgery.
  • Increased endometrial plasminogen activators are linked to HMB, leading to the use of antifibrinolytic agents.
  • Concerns regarding tranexamic acid's thrombogenic risk have been mitigated by studies showing comparable incidence to spontaneous thrombosis.

Purpose of the Study:

  • To evaluate the effectiveness of antifibrinolytic agents in reducing heavy menstrual bleeding.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) identified through comprehensive database searches (MEDLINE, EMBASE, Cochrane Library).
  • Inclusion criteria focused on reproductive-aged women with regular HMB treated with antifibrinolytics versus placebo or other medical therapies.

Related Experiment Videos

  • Seven trials were assessed, with four included in the meta-analysis; three crossover trials provided qualitative data.

    • Main Results:

    • Antifibrinolytic therapy significantly reduced objective measures of blood loss compared to placebo (WMD -94.0) and other treatments like mefenamic acid, norethisterone, and ethamsylate.
    • While objective improvements were noted, patient-perceived reduction in menstrual blood loss showed a non-significant trend favoring tranexamic acid.
    • No significant differences in side effects or treatment withdrawal were observed compared to placebo, NSAIDs, or oral progestagens; quality of life measures (flooding, leakage, sex life) improved with tranexamic acid.

    Conclusions:

    • Antifibrinolytic therapy, particularly tranexamic acid, is effective in reducing objective heavy menstrual bleeding compared to placebo and other medical interventions.
    • The treatment is well-tolerated, with no increased risk of side effects or withdrawal compared to alternatives.
    • Tranexamic acid demonstrates significant improvements in specific quality of life aspects, though further research is needed on patient perception and long-term safety outcomes.